BR112014007782A2 - compostos para transdução viral aperfeiçoada - Google Patents
compostos para transdução viral aperfeiçoadaInfo
- Publication number
- BR112014007782A2 BR112014007782A2 BR112014007782A BR112014007782A BR112014007782A2 BR 112014007782 A2 BR112014007782 A2 BR 112014007782A2 BR 112014007782 A BR112014007782 A BR 112014007782A BR 112014007782 A BR112014007782 A BR 112014007782A BR 112014007782 A2 BR112014007782 A2 BR 112014007782A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- viral transduction
- enhanced viral
- enhanced
- transduction
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000026683 transduction Effects 0.000 title 1
- 238000010361 transduction Methods 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541736P | 2011-09-30 | 2011-09-30 | |
| US61/541,736 | 2011-09-30 | ||
| PCT/US2012/057987 WO2013049615A1 (en) | 2011-09-30 | 2012-09-28 | Compounds for improved viral transduction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014007782A2 true BR112014007782A2 (pt) | 2017-04-11 |
| BR112014007782B1 BR112014007782B1 (pt) | 2021-06-01 |
Family
ID=47996444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014007782-7A BR112014007782B1 (pt) | 2011-09-30 | 2012-09-28 | Método para aumentar a eficiência de transdução lentiviral de células progenitoras ou células-tronco hematopoiéticas cd34+, bem como usos terapêuticos de composição compreendendo as ditas células e de pge2, 16,16-dimetil pge2, ou seu análogo |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9988644B2 (pt) |
| EP (4) | EP3656848B1 (pt) |
| JP (2) | JP6285863B2 (pt) |
| KR (1) | KR102011532B1 (pt) |
| CN (2) | CN103958667A (pt) |
| AU (1) | AU2012315699B2 (pt) |
| BR (1) | BR112014007782B1 (pt) |
| CA (1) | CA2850484C (pt) |
| CY (1) | CY1122654T1 (pt) |
| DK (2) | DK3269802T3 (pt) |
| EA (1) | EA032699B1 (pt) |
| ES (3) | ES2632444T5 (pt) |
| IL (2) | IL231812B (pt) |
| IN (1) | IN2014CN02518A (pt) |
| MX (2) | MX359398B (pt) |
| PT (2) | PT2760994T (pt) |
| SG (2) | SG11201401077PA (pt) |
| UA (1) | UA114796C2 (pt) |
| WO (1) | WO2013049615A1 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107523587A (zh) | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| KR102011532B1 (ko) | 2011-09-30 | 2019-08-16 | 블루버드 바이오, 인코포레이티드. | 개선된 바이러스 형질도입을 위한 화합물 |
| CN104684561A (zh) | 2012-08-01 | 2015-06-03 | 联合治疗公司 | 利用间充质干细胞的肺动脉高血压的治疗 |
| ES2713988T3 (es) | 2012-08-01 | 2019-05-24 | United Therapeutics Corp | Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| SG10202110062SA (en) | 2012-11-27 | 2021-11-29 | Childrens Medical Center | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
| EP3878452B1 (en) | 2013-01-09 | 2023-09-20 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
| JP6691048B2 (ja) * | 2013-10-24 | 2020-04-28 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
| US20170173083A1 (en) * | 2014-03-26 | 2017-06-22 | The Brigham And Women's Hospital, Inc. | Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells |
| BR112016024565A2 (pt) | 2014-04-25 | 2018-01-23 | Children's Medical Center Corporation | composições e métodos de tratar hemoglobinopatias |
| WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| RU2630654C2 (ru) * | 2015-07-29 | 2017-09-11 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов |
| CN105062979A (zh) * | 2015-08-21 | 2015-11-18 | 昆明理工大学 | 一种培养戊型肝炎病毒的方法 |
| IL261002B1 (en) * | 2016-02-12 | 2024-03-01 | Bluebird Bio Inc | Preparations of a VCN amplifier and methods of using them |
| EP3413896B1 (en) * | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| WO2017177137A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| CA3023257A1 (en) | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| KR102606101B1 (ko) | 2016-10-24 | 2023-11-27 | 유나이티드 쎄러퓨틱스 코포레이션 | 트레프로스티닐에 의한 msc 면역조절 특성의 향상 |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| BR112019020322A2 (pt) * | 2017-03-29 | 2020-04-28 | Bluebird Bio Inc | vetores e composições para o tratamento de hemoglobinopatias |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
| WO2019055814A2 (en) * | 2017-09-15 | 2019-03-21 | The Medical College Of Wisconsin, Inc. | EPOXYEICOSATRIENOIC ACID (EET) ANALOGUES TARGETING KIDNEYS |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN109207427B (zh) * | 2018-09-17 | 2020-12-08 | 诺未科技（银川）有限公司 | 一种将人造血祖细胞转变为造血干细胞的方法 |
| CN110799641B (zh) * | 2018-04-13 | 2021-02-19 | 诺未科技（北京）有限公司 | 丁酸钠的用途及含有丁酸钠的培养体系 |
| WO2019210301A1 (en) * | 2018-04-27 | 2019-10-31 | The Medical College Of Wisconsin, Inc. | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders |
| WO2020264488A1 (en) * | 2019-06-28 | 2020-12-30 | The Children's Hospital Of Philadelphia | Compositions and methods for treating anemia |
| AU2020365133A1 (en) * | 2019-10-16 | 2022-04-28 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| CN113106098B (zh) * | 2021-04-21 | 2022-04-01 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| CN113336833A (zh) * | 2021-06-04 | 2021-09-03 | 广州伯尼兹生物科技有限公司 | 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法 |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| WO2024033802A2 (en) | 2022-08-11 | 2024-02-15 | Fondazione Telethon Ets | Gene therapy |
| WO2024079644A1 (en) | 2022-10-11 | 2024-04-18 | Fondazione Telethon Ets | 3d cell culture methods |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
| WO1995000657A1 (en) | 1993-06-21 | 1995-01-05 | The Uab Research Foundation | Anti-sickling hemoglobin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5869039A (en) | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
| EP0783575B1 (en) | 1994-09-19 | 1999-06-16 | Massachusetts Institute Of Technology | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| EP0873049B1 (en) * | 1995-09-29 | 2006-05-10 | Indiana University Research and Technology Corporation | Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| WO1998000541A2 (en) | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| WO2000023567A2 (en) | 1998-10-16 | 2000-04-27 | Novartis Ag | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| KR20020022798A (ko) | 1999-08-13 | 2002-03-27 | 후미에 사토 | 프로스타글란딘 유도체 |
| EP2292657A1 (en) | 1999-11-12 | 2011-03-09 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
| ATE384704T1 (de) | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | Pyrazin-basierte hemmer der glycogen-synthase- kinase 3 |
| PT1132086E (pt) | 2000-01-31 | 2006-09-29 | Pfizer Prod Inc | Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| CA2446110C (en) | 2001-05-01 | 2013-06-25 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| AU2002347563A1 (en) | 2001-12-06 | 2003-06-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| WO2003056019A1 (en) | 2001-12-24 | 2003-07-10 | Es Cell International Pte Ltd | Method of transducing es cells |
| EP1471818A4 (en) | 2002-02-04 | 2007-03-28 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AU2003296958A1 (en) | 2002-12-13 | 2004-07-09 | Genetix Pharmaceuticals, Inc. | Therapeutic retroviral vectors for gene therapy |
| CA2519975C (en) | 2003-04-08 | 2013-07-02 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| ATE488252T1 (de) * | 2003-05-05 | 2010-12-15 | Virxsys Corp | Erhöhte transduktion mit abc- transportersubstratenhemmern |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| JP2008518013A (ja) | 2004-10-26 | 2008-05-29 | アラーガン、インコーポレイテッド | プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法 |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| WO2007041511A2 (en) | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| WO2007047372A2 (en) | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| ZA200808123B (en) | 2006-03-24 | 2010-03-31 | Childrens Medical Center | Method to modulate hematopoietic stem cell growth |
| ATE539170T1 (de) * | 2006-04-27 | 2012-01-15 | Univ Montreal | Abschätzung und verringerung des risikos von graft-versus-host-reaktion |
| US8241903B2 (en) | 2006-06-22 | 2012-08-14 | Yeda Research And Development Co., Ltd. | Catecholamine receptor modulation |
| WO2008070310A2 (en) | 2006-10-20 | 2008-06-12 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| EP2131840B1 (en) | 2007-03-07 | 2018-10-17 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| CN107523587A (zh) * | 2008-11-06 | 2017-12-29 | 印第安纳大学研究与技术公司 | 增强造血干细胞植入过程的材料和方法 |
| WO2010108028A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| ES2727787T3 (es) * | 2009-11-15 | 2019-10-18 | Univ Indiana Res & Tech Corp | Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2 |
| KR102011532B1 (ko) | 2011-09-30 | 2019-08-16 | 블루버드 바이오, 인코포레이티드. | 개선된 바이러스 형질도입을 위한 화합물 |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| JP6691048B2 (ja) * | 2013-10-24 | 2020-04-28 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| US10669528B2 (en) * | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| CA2993201A1 (en) * | 2015-07-21 | 2017-01-26 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
| EP3413896B1 (en) * | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| IL261002B1 (en) * | 2016-02-12 | 2024-03-01 | Bluebird Bio Inc | Preparations of a VCN amplifier and methods of using them |
| GB201706394D0 (en) * | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
-
2012
- 2012-09-28 KR KR1020147011495A patent/KR102011532B1/ko active IP Right Grant
- 2012-09-28 DK DK17173567.3T patent/DK3269802T3/da active
- 2012-09-28 UA UAA201403867A patent/UA114796C2/uk unknown
- 2012-09-28 CA CA2850484A patent/CA2850484C/en active Active
- 2012-09-28 ES ES12836507T patent/ES2632444T5/es active Active
- 2012-09-28 CN CN201280056851.7A patent/CN103958667A/zh active Pending
- 2012-09-28 US US14/348,572 patent/US9988644B2/en active Active
- 2012-09-28 EP EP19204363.6A patent/EP3656848B1/en active Active
- 2012-09-28 ES ES19204363T patent/ES2913633T3/es active Active
- 2012-09-28 SG SG11201401077PA patent/SG11201401077PA/en unknown
- 2012-09-28 EA EA201490627A patent/EA032699B1/ru unknown
- 2012-09-28 JP JP2014533413A patent/JP6285863B2/ja active Active
- 2012-09-28 ES ES17173567T patent/ES2769270T3/es active Active
- 2012-09-28 AU AU2012315699A patent/AU2012315699B2/en active Active
- 2012-09-28 DK DK12836507.9T patent/DK2760994T4/da active
- 2012-09-28 EP EP17173567.3A patent/EP3269802B1/en active Active
- 2012-09-28 SG SG10201602423TA patent/SG10201602423TA/en unknown
- 2012-09-28 PT PT128365079T patent/PT2760994T/pt unknown
- 2012-09-28 BR BR112014007782-7A patent/BR112014007782B1/pt not_active IP Right Cessation
- 2012-09-28 EP EP22161134.6A patent/EP4095236A1/en not_active Withdrawn
- 2012-09-28 EP EP12836507.9A patent/EP2760994B2/en active Active
- 2012-09-28 CN CN201810168851.5A patent/CN108220246B/zh active Active
- 2012-09-28 WO PCT/US2012/057987 patent/WO2013049615A1/en active Application Filing
- 2012-09-28 MX MX2014003923A patent/MX359398B/es active IP Right Grant
- 2012-09-28 PT PT171735673T patent/PT3269802T/pt unknown
- 2012-09-28 IN IN2518CHN2014 patent/IN2014CN02518A/en unknown
-
2014
- 2014-03-30 IL IL231812A patent/IL231812B/en active IP Right Grant
- 2014-03-31 MX MX2018011791A patent/MX2018011791A/es unknown
-
2018
- 2018-02-02 JP JP2018017184A patent/JP6745826B2/ja active Active
- 2018-06-04 US US15/997,643 patent/US10501759B2/en active Active
-
2019
- 2019-10-28 US US16/665,892 patent/US10907177B2/en active Active
-
2020
- 2020-01-22 CY CY20201100056T patent/CY1122654T1/el unknown
- 2020-12-17 US US17/125,930 patent/US11834668B2/en active Active
-
2021
- 2021-02-23 IL IL281045A patent/IL281045B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281045B (en) | Compounds for enhanced cellular transduction | |
| SMT201600308B (it) | Composti di benzene arile-o eteroarile-sostituiti | |
| DE112012003620T8 (de) | Kartusche | |
| CR20140147A (es) | Inhibidores de aplicación viral | |
| CR20130231A (es) | Compuestos antivirales | |
| BR112014007781A2 (pt) | compostos anti-virais | |
| BR112014012016A2 (pt) | compostos | |
| BR112013029138A2 (pt) | procedimento para assinatura digital múltipla | |
| CO6910197A2 (es) | Compuestos novedosos | |
| BR112014000879A2 (pt) | deflegmador | |
| DE112012003585A5 (de) | Schneideinrichtung | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| FI20115024A (fi) | Leikkuuterä | |
| CO6970601A2 (es) | Nueva combinación | |
| BR112014007599A2 (pt) | compostos anti-virais | |
| DE112011104936A5 (de) | Stanzstauchniet | |
| BR112013022508A2 (pt) | novos compostos de azaespirodecanona | |
| DE112012000958A5 (de) | Handsäge | |
| ES1074812Y (es) | Cuadro para bicicleta | |
| DE112012002458A5 (de) | Hydrotransformator | |
| DE112012000819A5 (de) | Gurtbandfänger | |
| DE112012001294T8 (de) | Umspritzungsverfahren | |
| ES1074173Y (es) | Pieza para solados | |
| FR2978106B1 (fr) | Voilure amovible |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: BLUEBIRD BIO, INC (US) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2012, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: BLUEBIRD BIO, INC. (US) Free format text: RETIFICACAO DO DESPACHO 25.7 ? ALTERACAO DE SEDE PUBLICADO NA RPI NO 2570, DE 07/04/2020.ONDE SE LE: 60 BINNEY ST. CAMBRIDGE, MA 02141, EUA. LEIA-SE: 60 BINNEY ST. CAMBRIDGE, MA 02142, EUA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2742 DE 25-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |